How to Navigate the Transition to IQSSS (INESS-INSPQ MERGER)

Examine the IQSSS decision matrix and analyze the operational changes in the drug evaluation process. Optimize how you navigate the transition to IQSSS. Adopt best practices to: 

• Impact the new institute’s mandate on HTA timelines and transparency.
• Improve “social and preventive” value, benchmarking the increased weighting of public health data and disease prevention.
• Transform the 2027 submission cycle by identifying critical success factors for new drug submissions.
• Amplify santé Québec and institutional governance, evaluating the new relationship in drug procurement and hospital access.
• Enhance the “Quebec Advantage” by formulating strategies to preserve accelerated access timelines within its modernized health and social services infrastructure.

 Determine the requirements for recalibrating Quebec market access strategies to ensure your continuous alignment with the province’s evolving HTA leadership and fiscal priorities.